Cost-effectiveness of subcutaneous pertuzumab, trastuzumab, and hyaluronidase-zzxf for the treatment of high-risk HER2+ early breast cancer
Sussell, Jesse, Roth, Joshua A., Hansen, Svenn, Meyer, Craig S., Fung, Anita M.
Published in Journal of clinical oncology (20.05.2021)
Published in Journal of clinical oncology (20.05.2021)
Get full text
Journal Article
Preliminary analysis of an expanded access study of the fixed-dose combination of pertuzumab (P) and trastuzumab (H) for subcutaneous injection (PH FDC SC) for at-home administration (admin) in patients (pts) with HER2-positive (HER2+) breast cancer (BC) during the COVID-19 pandemic
Dang, Chau T., Tolaney, Sara M., Riaz, Fauzia, Tan, Antoinette R., Tkaczuk, Katherine H. R., Yu, Anthony Francis, Liu, Jennifer, Fung, Anita M., Yang, Anna, Day, Bann-mo, Rugo, Hope S.
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
Planned interim analysis of PATRICIA: An open-label, single-arm, phase II study of pertuzumab (P) with high-dose trastuzumab (H) for the treatment of central nervous system (CNS) progression post radiotherapy (RT) in patients (pts) with HER2-positive metastatic breast cancer (MBC)
Lin, Nancy U., Stein, Alisha, Nicholas, Alan, Fung, Anita M., Kumthekar, Priya, Ibrahim, Nuhad K., Pegram, Mark D.
Published in Journal of clinical oncology (20.05.2017)
Published in Journal of clinical oncology (20.05.2017)
Get full text
Journal Article